Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Supernus Pharmaceuticals Inc    SUPN

SUPERNUS PHARMACEUTICALS INC (SUPN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
38.65(c) 38.1(c) 39.4(c) 39.15(c) 38.35(c) Last
433 110 306 408 383 946 332 469 447 381 Volume
+3.90% -1.42% +3.41% -0.63% -2.04% Change
More quotes
Financials ($)
Sales 2017 301 M
EBIT 2017 87,5 M
Net income 2017 58,1 M
Debt 2017 -
Yield 2017 -
Sales 2018 389 M
EBIT 2018 122 M
Net income 2018 85,7 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 36,46
P/E ratio 2018 24,78
Capi. / Sales2017 6,67x
Capi. / Sales2018 5,16x
Capitalization 2 007 M
More Financials
Company
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases.Its neurology portfolio consists of Oxtellar XR and Trokendi, which treats patients with epilepsy.It also develops product candidates for the treatment of... 
Sector
Pharmaceuticals
Calendar
02/27 | 11:00pmEarnings Release
More about the company
Surperformance© ratings of Supernus Pharmaceuticals I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUPERNUS PHARMACEUTICALS I
02/15SUPERNUS PHARMACEUTICALS : Researchers Submit Patent Application, "Methods of Pr..
AQ
02/14SUPERNUS PHARMACEUTICALS,INC. (NASDA : SUPN) Files An 8-K Results of Operations ..
AQ
02/12Supernus to Host Fourth Quarter and Full Year 2017 Earnings Conference Call
GL
01/22SUPERNUS PHARMACEUTICALS INC : Today’s Research Reports on Trending Tickers: Sup..
AC
01/16SUPERNUS PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Conti..
AQ
01/13SUPERNUS PHARMACEUTICALS : Mourns the Loss of Board Member William Nuerge
AQ
01/12Supernus Mourns the Loss of Board Member William Nuerge
GL
01/11SUPERNUS PHARMACEUTICALS : Patent Issued for Modified Release Preparations Conta..
AQ
01/05SUPERNUS PHARMACEUTICALS : to Present at the 2018 J.P. Morgan Healthcare Confere..
AQ
01/04SUPERNUS PHARMACEUTICALS,INC. (NASDA : SUPN) Files An 8-K Other Events
AQ
More news
Sector news : Specialty & Advanced Pharmaceuticals
03:15pNOVARTIS : CEO Steers Drug Maker Back to R&D
DJ
02/16S&P 500 caps off strongest week in five years
RE
02/16ASTRAZENECA : U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
RE
02/16NOVARTIS : readies to auction U.S. generic pills business - sources
RE
02/16Backstory - Warren Buffett's Valentine's Day surprise for investors
RE
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
11:23aCrossmark Global Holdings Inc. Reduces Stake in Supernus Pharmaceuticals Inc .. 
02/10Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Supernus Pharma.. 
02/10Want the latest upgrades & downgrades for $MRC $SUPN $TGTX $DCIN $WAGE? C.. 
02/09Stephens Investment Management Group LLC Buys Shares of 183,593 Supernus Phar.. 
02/01Thursday's top Analyst Upgrades and Downgrades PART 2 $FB $FLXN $MSFT $PRGO $.. 
More tweets
Qtime:43
News from SeekingAlpha
02/01Premarket analyst action - healthcare 
01/18Premarket analyst action - healthcare 
2017YOUR DAILY PHARMA SCOOP : Intercept Updates On NASH Trial, GW Pharmaceuticals Pr.. 
2017B. Riley raises its Supernus Pharma price target 
2017BIOTECH FORUM DAILY DIGEST : Impacts Of Tax Reform 
Chart SUPERNUS PHARMACEUTICALS I
Duration : Period :
Supernus Pharmaceuticals I Technical Analysis Chart | SUPN | US8684591089 | 4-Traders
Technical analysis trends SUPERNUS PHARMACEUTICALS I
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 52,4 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Jack A. Khattar President, CEO, Secretary & Director
Charles W. Newhall Chairman
Gregory S. Patrick Chief Financial Officer & Vice President
Padmanabh P. Bhatt Chief Scientific Officer & Senior Vice President
Stefan K. F. Schwabe Chief Medical Officer, EVP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SUPERNUS PHARMACEUTICALS INC-1.13%2 020
ABBVIE16.93%180 524
MERCK KGAA-8.06%13 375
KYOWA HAKKO KIRIN CO LTD4.50%12 695
JAZZ PHARMACEUTICALS PLC8.31%8 743
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD14.51%6 883